Vertex Pharmaceuticals reported third-quarter 2024 financial results, beating estimates due to strong demand for its cystic fibrosis treatments. The company raised its annual revenue forecast. Analysts had estimated $2.69 billion in revenue and $4.10 in earnings per share. The WhisperNumber community expected $4.20 in earnings per share, 6 cents ahead of analyst estimates. Illumina also reported its third-quarter earnings, surpassing IBES estimates with an adjusted EPS of $1.14 and revenue of $1.08 billion. The company reported cash and equivalents of $869 million. NXP Semiconductors reported third-quarter revenue of $3.25 billion, down 5% year-over-year and up 4% quarter-over-quarter. The company provided a disappointing fourth-quarter forecast due to macroeconomic concerns and weaknesses in the automotive industry. NXP's GAAP EPS was $2.79, with a GAAP Gross Margin of 57.4% and a GAAP Operating Margin of 30.5%.